Drug intelligence / Profile preview

PF-07999415

Development stage: Phase 1
Lead developer: Pfizer
Administration: Subcutaneous

Overview

PF-07999415 is an investigational drug developed by Pfizer being evaluated primarily for its safety, tolerability, and pharmacokinetics in healthy adult participants. The drug is currently in Phase 1 clinical trials, where different doses are being tested via subcutaneous injection. The specific mechanism of action and therapeutic target of PF-07999415 have not been disclosed. No indications other than healthy volunteer studies have been announced as of July 2025.[1][2][3][5][6][7]

Beyond the preview

Go deeper on PF-07999415.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07999415.

Explore the full profile